Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400666 | 0.87 | SMN1; SMN2 (0.44) | HRH3NR4A2 | |
| SCHEMBL6395332 | 0.86 | MRGPRX4 (0.46) | KDM4E | |
| SCHEMBL6397512 | 0.84 | MRGPRX4 (0.47) | KDM4E | |
| SCHEMBL6397846 | 0.82 | RAB9A (0.53) | HRH3KDM4E | |
| SCHEMBL10328598 | 0.81 | LDHA (0.54) | FFAR1RXRARXRBRXRGNR4A2 | |
| SCHEMBL10494168 | 0.77 | MEN1 (0.50) | TP53TSHR | |
| SCHEMBL10328548 | 0.77 | MEN1 (0.50) | TP53TSHR | |
| SCHEMBL6402963 | 0.77 | MRGPRX4 (0.48) | KDM4ETSHR | |
| SCHEMBL10328605 | 0.76 | MEN1 (0.48) | TP53TSHR | |
| SCHEMBL10328642 | 0.74 | PTGER4 (0.37) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | claimed |
| US-6552073-B1 | As anti-proliferative agent; for therapy of cancer | EXONHIT THERAPEUTICS SA (FR) | 2003-04-22 | — | — | US | claimed |
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
| US-6552073-B1 | As anti-proliferative agent; for therapy of cancer | EXONHIT THERAPEUTICS SA (FR) | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | HRH3 2816/4885KDM4E 1761/4885PPARG 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.